Navigation Links
Imaging Diagnostic Systems Generates Cash From Building Sale
Date:9/19/2007

$4.4 Million Available to Advance Premarket Approval Study and Current

Operations

FORT LAUDERDALE, Fla., Sept. 19 /PRNewswire-FirstCall/ -- Imaging Diagnostic Systems, Inc., (OTC Bulletin Board: IMDS) a pioneer in laser optical breast cancer imaging systems, announced completion of a financing arrangement intended to reduce its dependency on equity financing.

The Company has sold its headquarters building for $4.4 million in cash pursuant to a sale/leaseback agreement.

(Logo: http://www.newscom.com/cgi-bin/prnh/20040412/IMDSLOGO)

Tim Hansen, IMDS Chief Executive Officer, commented, "We are very pleased to have completed this arrangement. IMDS is at a critical point in its history; the market has never been more ready for a product like our CT Laser Mammography system (CTLM(R)). We have grown to eight sites participating in our U.S. clinical trials, and we may add more to accelerate data collection. We have tapped a cash source at the right time to support the PMA process without diluting our investors with continued drawing on our equity funding agreement. All of this is good news for our shareholders, who have patiently supported the Company through the lengthy product development stages. We believe this sale/leaseback move will help keep us financially and strategically poised to advance the PMA process and bring an exciting and revolutionary CTLM breast cancer imaging system to women worldwide."

Details of the sale/leaseback agreement are available in an 8K filing with the SEC.

About Imaging Diagnostic Systems, Inc.

Imaging Diagnostic Systems, Inc. has developed a revolutionary new imaging device to aid in the detection and management of breast cancer. The CTLM system is a breast imaging system that utilizes patented continuous wave laser technology and computer algorithms to create 3-D images of the breast. The procedure is non-invasive, painless, and does not expose the patient to ionizing radiation or painful breast compression. CTLM is designed to be used in conjunction with mammography. It reveals information about blood distribution in the breast and may visualize the process of angiogenesis, which usually accompanies tumor growth.

Imaging Diagnostic Systems is currently collecting data from clinical sites for the future filing of an FDA Premarket Approval (PMA) for the Computed Tomography Laser Mammography system to be used as an adjunct to mammography. The FDA has determined that the Company's clinical study is a non-significant risk (NSR) investigational device study under 812.3(m) of the investigational device exemptions (IDE) regulation (21 CFR 812). The CTLM system is limited by United States Federal Law to investigational use only in the United States. The CTLM system has received other registrations including CE, CMDCAS Canadian License, China SFDA, UL, ISO 9001:2000, ISO 13485:2003 and FDA export certification.

For more information, visit our website: http://www.imds.com

As contemplated by the provisions of the Safe Harbor section of the Private Securities Litigation Reform Act of 1995, this news release may contain forward-looking statements pertaining to future, anticipated, or projected plans, performances and developments, as well as other statements relating to future operations. All such forward-looking statements are necessarily only estimates or predictions of future results or events and there can be no assurance that actual results or events will not materially differ from expectations. Further information on potential factors that could affect Imaging Diagnostic Systems, Inc., is included in the Company's filings with the Securities and Exchange Commission. We expressly disclaim any intent or obligation to update any forward-looking statements.

Investor Relations:

Rick Lutz

(404) 261-1196

lcgroup@mindspring.com

Media Contact:

Elizabeth Williams

(954) 581-9800

williams@imds.com


'/>"/>
SOURCE Imaging Diagnostic Systems, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Optimized Imaging of Protein Gels Stained with Coomassie Brilliant Blue Dye
2. Detect Released Oligosaccharides Using the Eagle Eye II Still Video Imaging System
3. Imaging Chemiluminescent Western Blots
4. Eagle Eye Optical Filter Optimized for Imaging Silver-Stained Gels
5. Imaging and Analysis of DIGE Product Information Sheet, Rev B
6. The development of a CXCR2 chemokine receptorbinding assay using the LEADseeker Multimodality Imaging System
7. Performance of the AMARA HitHunter Chemiluminescence Kinase Assay with the LEADseeker Multimodality Imaging System
8. The development of a melanocortin MC4 receptor binding assay using the LEADseeker Multimodality Imaging System
9. The development of a melanocortin MC5 receptor binding assay using the LEADseeker Multimodality Imaging System
10. The development of a calcitonin-gene related peptide (CGRP) receptor-binding assay using the LEADseeker Multimodality Imaging System
11. Utilization of Donkey Anti-Rabbit PS SPA Imaging Beads in the quantitative measurement of cAMP in cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ... October 11, 2017 , ... The CRISPR-Cas9 ... enabling overexpression experiments and avoiding the use of exogenous expression plasmids. The simplicity ... for performing systematic gain-of-function studies. , This complement to loss-of-function studies, such ...
(Date:10/11/2017)... and LAGUNA HILLS, Calif. , Oct. ... Cancer Research, London (ICR) and University ... SKY92, SkylineDx,s prognostic tool to risk-stratify patients with multiple myeloma ... MUK nine . The University of Leeds ... partly funded by Myeloma UK, and ICR will perform the ...
(Date:10/10/2017)... (PRWEB) , ... October 10, ... ... development-stage cancer-focused pharmaceutical company advancing targeted antibody-drug conjugate (ADC) therapeutics, today confirmed ... targeted HPLN (Hybrid Polymerized Liposomal Nanoparticle), a technology developed in collaboration with ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... business process optimization firm for the life sciences and healthcare industries, announces a ... in San Francisco. , The presentation, “Automating GxP Validation for Agile Cloud Platforms,” ...
Breaking Biology Technology:
(Date:4/19/2017)... New York , April 19, 2017 ... competitive, as its vendor landscape is marked by the ... the market is however held by five major players ... Safran. Together these companies accounted for nearly 61% of ... of the leading companies in the global military biometrics ...
(Date:4/13/2017)... India , April 13, 2017 According to ... Proofing, Identity Authentication, Identity Analytics, Identity Administration, and Authorization), Service, Authentication Type, ... MarketsandMarkets™, the IAM Market is expected to grow from USD 14.30 Billion ... Growth Rate (CAGR) of 17.3%. ... MarketsandMarkets ...
(Date:4/11/2017)... MELBOURNE, Florida , April 11, 2017 ... "Company"), a security technology company, announces the appointment of independent ... John Bendheim to its Board of Directors, furthering the ... ... behalf of NXT-ID, we look forward to their guidance and ...
Breaking Biology News(10 mins):